Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028263 | 1.00 | KDM4E (0.68) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1298567 | 0.98 | KDM4E (0.66) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2742565 | 0.94 | KDM4E (0.68) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL17821823 | 0.93 | KDM4E (0.66) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5209173 | 0.91 | MTNR1A (0.64) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3272392 | 0.91 | SLC2A1 (0.54) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31040310 | 0.90 | KDM4E (0.54) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5628566 | 0.89 | SLC2A1 (0.52) | KDM4EATMCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3712764 | 0.88 | MEN1 (0.60) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23206799 | 0.88 | KDM4E (0.59) | KDM4EATMCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536584-B | Synthesis method of norlinderane hydrochloride | 珠海润都制药股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023109802-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109802-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-115536584-A | Synthetic method of higenamine hydrochloride | 珠海润都制药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-115260185-A | Deuterated derivatives of corydaline and stepholidine and preparation method thereof | 杨征 | 2022-11-01 | — | — | CN | disclosed |
| EP-3438108-B1 | PHENYL [A]INDOLE[2,3-G]QUINOLIZINE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-08-10 | — | — | EP | disclosed |
| EP-2848617-B1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-01-12 | — | — | EP | disclosed |
| CN-109071541-B | Phenyl [ a ] indole [2,3-g ] quinolizine compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| WO-1997014677-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID DERIVATIVES AS MICROBICIDES | NOVARTIS AG (CH) | 1997-04-24 | — | — | WO | disclosed |
| EP-0618900-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5519034-A | ANALGESICS | THE BOOTS COMPANY PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| EP-0618900-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| US-4612313-A | Pharmaceutical phenylacetonitrile derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1986-09-16 | — | — | US | disclosed |
| EP-0175249-A2 | Phenylacetonitrile derivatives | Roche Diagnostics GmbH (DE) | 1986-03-26 | — | — | EP | disclosed |
| US-4191765-A | 1-Aryloxy-2-hydroxy-3-aminopropanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4107165-A | ANTICOAGULANTS | ENDO LABORATORIES (US) | 1978-08-15 | — | — | US | disclosed |
| US-4001244-A | 1-ARYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE CARBONYL CHLORIDES | G. D. SEARLE & CO. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | KDM4E 2429/4885ATM 1177/4885CYP1A2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.